Crescendo Biologics Appoints Chair
This article was originally published in Scrip
Crescendo Biologics Ltd. has appointed Kevin Johnson non-executive chair of the board of directors – effective immediately. Johnson has 27 years' experience in antibody development and previously was CEO of Netherlands-based PanGenetics, an antibody development company. He also held various roles at Cambridge Antibody Technology, which eventually led to his appointment as research director and chief technology officer. Since 2003 he has been working in the life science team at Index Ventures.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.